Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
ALXA similar filings
- 9 May 11 Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
- 3 May 11 Alexza Prices $16.1 Million Registered Direct Offering
- 15 Mar 11 Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
- 22 Feb 11 Departure of Directors or Certain Officers
- 4 Feb 11 Departure of Directors or Certain Officers
- 21 Jan 11 Departure of Directors or Certain Officers
- 18 Jan 11 Alexza Pharmaceuticals Completes End-of-Review Meeting with FDA for AZ-004 (Staccato® Loxapine) NDA
Filing view
External links
Exhibit 10.1
Name and Title | Stock Option Awards | |
Thomas B. King President and Chief Executive Officer | 213,143 | |
James V. Cassella, Ph.D. Senior Vice President, Research and Development | 104,258 | |
August J. Moretti Senior Vice President, Chief Financial Officer, General Counsel and Secretary | 75,746 | |
Michael J. Simms Senior Vice President, Operations and Quality | 61,076 |